All In MedTech

Device Trial Radar · NCT07021014

NightWare and Cardiovascular Health in Women With PTSD

Improving Cardiovascular Health in Women With PTSD by Treating Trauma-Related Nightmares With NightWare

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Aug 6, 2025

Primary completion

Jul 2028

Study completion Jul 2028

Sponsor

Lead sponsor
University of Colorado, DenverAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ludeman Family Center for Women's Health Research
First posted
Jun 13, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Female only, from 22 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether NightWare therapeutic intervention improves biomarkers of vascular and renal function in premenopausal women with PTSD-related nightmares, and examine whether these improvements restore them to levels observed in age-matched women without PTSD.

Conditions

  • Post Traumatic Stress Disorder
  • Cardiovascular Diseases
  • Autonomic Dysfunction
  • Vascular Stiffness
  • Nightmare
  • Endothelial Dysfunction
  • Kidney Diseases
  • Renal Dysfunction
  • Trauma and Stressor Related Disorders

Interventions

  • NightWareDevice

    A wearable digital therapeutic platform consisting of an Apple Watch and iPhone pre-provisioned with Nightware intervention app that will deliver a mild vibration to the watch after detecting individual having a nightmare based on Nightware proprietary algorithm, arousing the individual and disrupting nightmare without awakening.

  • Sham NightWareDevice

    NightWare decive will not deliver an intervention (i.e., no vibration)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Brachial artery flow-mediated dilation (FMD)Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • University of Colorado CCTSI CTRC

    Denver, Colorado · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.